Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients

Anti-PD-1 antibodies revolutionized the treatment of advanced melanoma patients. However, one out of three do not respond to this therapy, with an overall poor prognosis. Identification of predictive biomarkers in patients receiving immune-based therapies is necessary for minimizing risk of toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Giunta, Emilio Francesco, Barra, Giusi, De Falco, Vincenzo, Argenziano, Giuseppe, Napolitano, Stefania, Vitale, Pasquale, Zanaletti, Nicoletta, Terminiello, Marinella, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Davide, De Palma, Raffaele, Ciardiello, Fortunato, Troiani, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573589/
https://www.ncbi.nlm.nih.gov/pubmed/33077770
http://dx.doi.org/10.1038/s41598-020-72711-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573589/
https://www.ncbi.nlm.nih.gov/pubmed/33077770
http://dx.doi.org/10.1038/s41598-020-72711-2

Ejemplares similares